DAFTAR PUSTAKA

Achmad, I., Jasirwan, C. O. M., Rajabto, W., Abdullah, M., Nababan, S. H. H., Nasution, S. A., Koesnoe, S., & Sari, N. K. (2024). Kesintasan pasien karsinoma hepatoselular: Sebuah studi komprehensif tentang pengaruh awitan dini versus lambat dan faktor determinannya. *Jurnal Penyakit Dalam Indonesia, 11*(3), Article 5.

Bai, D. S., Zhang, C., Chen, P., Jin, S. J., & Jiang, G. Q. (2017). The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. *Scientific Reports*, *7*(1). doi: 10.1038/s41598-017-12834-1

Brar, G., Greten, T. F., Graubard, B. I., Mcneel, T. S., Petrick, J. L., Mcglynn, K. A., & Altekruse, S. F. (n.d.). Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatology Communications*, *4*(10), 2020. doi: 10.1002/hep4.1564/suppinfo

Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: An update. *Hepatology, 53*(3), 1020–1022. doi: 10.1002/hep.24199

Cabibbo, G., et al. (2012). Age is not a barrier to liver resection for hepatocellular carcinoma: Results from a multicenter Italian study. *Journal of Hepatology, 56*(1), 75–83. doi: 10.1016/j.jhep.2011.07.012

Chan, S. L., et al. (2009). Use of AFP in diagnosis and monitoring of hepatocellular carcinoma. *Expert Review of Anticancer Therapy, 9*(4), 491–499. doi: 10.1586/era.09.6El-Serag, H. B. (2011). Hepatocellular Carcinoma. In N Engl J Med (Vol. 365).

European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology, 69*(1), 182–236. doi: 10.1016/j.jhep.2018.03.019

Facciorusso, A., Del Prete, V., Antonino, M., Neve, V., Amoruso, A., Crucinio, N., Di Leo, A., & Barone, M. (2015). Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation. *Hepatology Research*, *45*(10), E62–E72. doi: 10.1111/hepr.12458

Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Xu, D.-Z., Hernandez, S., Liu, J., Huang, C., Mulla, S., Wang, Y., Lim, H. Y., … Cheng, A.-L. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New England Journal of Medicine*, *382*(20), 1894–1905. doi: 10.1056/nejmoa1915745

Forner, A., Reig, M., & Bruix, J. (2018). Hepatocellular carcinoma. In The Lancet (Vol. 391, Issue 10127, pp. 1301–1314). Lancet Publishing Group. doi: 10.1016/S0140-6736(18)30010-2

Fu, Y., Yang, W., Wu, W., et al. (2022). Adjuvant lenvatinib after liver resection for hepatocellular carcinoma with microvascular invasion: A multicenter retrospective study. *BMC Cancer, 22*(1), 1–10. doi: 10.1186/s12885-022-09203-7

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J. L., Schirmacher, P., & Vilgrain, V. (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, *69*(1), 182–236. doi: 10.1016/j.jhep.2018.03.019

Hasan, I., Gani, R. A., Sulaiman, A. S., Kurniawan, J., Lesmana, C. R. A., Jasirwan, C. O. M., Nababan, S. H. H., Kalista, K. F., Aprilicia, G., & Teressa, M. (2023). Profil klinis dan kesintasan pasien karsinoma sel hati di rumah sakit rujukan tersier Indonesia tahun 2015–2021. *Jurnal Penyakit Dalam Indonesia, 10*(2), 90–95.

Hasegawa, K., Takemura, N., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., Iijima, H., Ueshima, K., Ohkawa, K., Genda, T., Tsuchiya, K., Torimura, T., Ikeda, M., Furuse, J., Akahane, M., … Tateishi, R. (2023). Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). *Hepatology Research*, *53*(5), 383–390. doi: 10.1111/hepr.13892

Hefaiedh, R., Ennaifer, R., Romdhane, H., Ben Nejma, H., Arfa, N., Belhadj, N., Gharbi, L., Khalfallah, T., Hefaiedh, R., Ennaifer, R., Romdhane, H., Nejma, H. Ben, Arfa, N., Belhadj, N., Gharbi, L., & Khalfallah, T. (n.d.). *Gender difference in patients with hepatocellular carcinoma*.

Hosmer, D. W., Lemeshow, S., & Sturdivant, R. X. (2013). *Applied logistic regression* (3rd ed.). Hoboken: Wiley. doi: 10.1002/9781118548387

Hsu, C. Y., Lee, Y. H., Hsia, C. Y., Huang, Y. H., Su, C. W., Lin, H. C., Lee, R. C., Chiou, Y. Y., Lee, F. Y., & Huo, T. I. (2013). Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. *Hepatology*, *57*(1), 112–119. doi: 10.1002/hep.25950

Hung, Y. W., Lee, I. C., Chi, C. T., Lee, R. C., Liu, C. A., Chiu, N. C., Hwang, H. E., Chao, Y., Hou, M. C., & Huang, Y. H. (2024). Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. *Liver Cancer*, *13*(1), 29–40. doi: 10.1159/000530950

Kaibori, M., Kon, M., Kitawaki, T., Kawaura, T., Hasegawa, K., Kokudo, N., Ariizumi, S., Beppu, T., Ishizu, H., Kubo, S., Kamiyama, T., Takamura, H., Kobayashi, T., Kim, D. S., Wang, H. J., Kim, J. M., Han, D. H., Park, S. J., Kang, K. J., … Yamamoto, M. (2017). Comparison of anatomic and non-

anatomic hepatic resection for hepatocellular carcinoma. *Journal of Hepato-Biliary-Pancreatic Sciences*, *24*(11), 616–626. doi: 10.1002/jhbp.502

Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2023). Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. In Biomedicines (Vol. 11, Issue 4). MDPI. doi: 10.3390/biomedicines11041166

Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., Baron, A., Park, J. W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, T. R. J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., … Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *The Lancet*, *391*(10126), 1163–1173. doi: 10.1016/S0140-6736(18)30207-1

Kementerian Kesehatan Republik Indonesia. (2022). *Peraturan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/1355/2022 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati pada Dewasa di Indonesia*. Jakarta: Kementerian Kesehatan RI

Lencioni, R., Petruzzi, P., & Crocetti, L. (2013). Chemoembolization of hepatocellular carcinoma. *Seminars in Interventional Radiology*, *30*(1), 3–11. doi: 10.1055/s-0033-1333648

Liu, Y., & Liu, L. (2022). Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. In Cancers (Vol. 14, Issue 18). MDPI. doi: 10.3390/cancers14184473

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021). Hepatocellular carcinoma. In Nature Reviews Disease Primers (Vol. 7, Issue 1). Nature Research. doi: 10.1038/s41572-020-00240-3

Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., Rodés, J., & Bruix, J. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. *Lancet*, *359*(9319), 1734–1739. doi: 10.1016/S0140-6736(02)08649-X

Loho, I. M., Hasan, I., Rinaldi, C., Dewiasty, E., & Gani, R. A. (2016). Hepatocellular carcinoma in a tertiary referral hospital in Indonesia: Lack of improvement of one-year survival rates between 1998-1999 and 2013-2014. *Asian Pacific Journal of Cancer Prevention*, *17*(4), 2165–2170. doi: 10.7314/APJCP.2016.17.4.2165

Lopes, F. de L. M., Coelho, F. F., Kruger, J. A. P., Fonseca, G. M., Araujo, R. L. C. de, Jeismann, V. B., & Herman, P. (2016). Influence of Hepatocellular Car cinoma Etiology In The Survival After Resection. *Arquivos Brasileiros de*

Cirurgia Digestiva : ABCD = Brazilian Archives of Digestive Surgery, *29*(2), 105–108. doi: 10.1590/0102-6720201600020010

Marrero, J. A., et al. (2018). Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. *Gastroenterology, 154*(3), 557–573. doi: 10.1053/j.gastro.2017.10.039

Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018). Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*, *68*(2), 723–750. doi: 10.1002/hep.29913

Massarweh, N. N., & El-Serag, H. B. (2017). Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. In Cancer Control (Vol. 24, Issue 3). SAGE Publications Ltd. doi: 10.1177/1073274817729245

Matsuki, M., Adachi, Y., Ozawa, Y., et al. (2018). Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. *Cancer Medicine, 7*(6), 2641–2653. doi: 10.1002/cam4.1506

Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., Adam, R., Neuhaus, P., Salizzoni, M., Bruix, J., Forner, A., De Carlis, L., Cillo, U., Burroughs, A. K., Troisi, R., … Majno, P. (2009). *Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis*. doi: 10.1016/S1470

Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., Holzner, M. L., Frankul, L., Chan, W., Fobar, A., Florman, S., & Yao, F. Y. (2021). Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. *Gastroenterology*, *161*(5), 1502–1512. doi: 10.1053/j.gastro.2021.07.033

Morgan, T. R., Mandayam, S., & Jamal, M. M. (2004). Alcohol and hepatocellular carcinoma. *Gastroenterology*, *127*(5 SUPPL.). doi: 10.1053/j.gastro.2004.09.020

Müller, L., Stoehr, F., Mähringer-Kunz, A., Hahn, F., Weinmann, A., & Kloeckner, R. (2021). Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *Journal of Hepatocellular Carcinoma*, *Volume 8*, 403–419. doi: 10.2147/jhc.s285735

Nishikawa, H., & Osaki, Y. (2015). Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. In Mediators of Inflammation (Vol. 2015). Hindawi Publishing Corporation. doi: 10.1155/2015/872152

Oken, M. M., et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. *American Journal of Clinical Oncology, 5*(6), 649–655. doi: 10.1097/00000421-198212000-00014

Omata, M., Cheng, A. L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K. H., Chawla, Y. K., Shiina, S., Jafri, W., Payawal, D. A., Ohki, T., Ogasawara, S., Chen, P. J., Lesmana, C. R. A., Lesmana, L. A., Gani, R. A., Obi, S., … Sarin, S. K. (2017). Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. In Hepatology International (Vol. 11, Issue 4, pp. 317–370). Springer India. doi: 10.1007/s12072-017-9799-9

Papatheodoridis, G. V., et al. (2015). Antiviral therapy for hepatitis B and C in patients with cirrhosis and hepatocellular carcinoma. *Journal of Hepatology, 62*(2), 396–408. doi: 10.1016/j.jhep.2014.10.029

Piscaglia, F., Terzi, E., Cucchetti, A., Trimarchi, C., Granito, A., Leoni, S., Marinelli, S., Pini, P., & Bolondi, L. (2013). Treatment of hepatocellular carcinoma in Child-Pugh B patients. *Digestive and Liver Disease*, *45*(10), 852–858. doi: 10.1016/j.dld.2013.03.002

Poon, R. T., Fan, S. T., Lo, C. M., et al. (2000). Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. *Journal of Clinical Oncology, 18*(5), 1094–1101. doi: 10.1200/JCO.2000.18.5.1094

Raffetti, E., Portolani, N., Molfino, S., Mentasti, S., Baiocchi, G. L., Magoni, M., & Donato, F. (2021). Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s. *Clinics and Research in Hepatology and Gastroenterology*, *45*(1). doi: 10.1016/j.clinre.2020.04.004

Raoul, J. L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019). Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. In Cancer Treatment Reviews (Vol. 72, pp. 28–36). W.B. Saunders Ltd. doi: 10.1016/j.ctrv.2018.11.002

Reig, María, Forner, A., Ávila, M. A., Ayuso, C., Mínguez, B., Varela, M., Bilbao, I., Bilbao, J. I., Burrel, M., Bustamante, J., Ferrer, J., Gómez, M. Á., Llovet, J. M., De la Mata, M., Matilla, A., Pardo, F., Pastrana, M. A., Rodríguez-Perálvarez, M., Tabernero, J., … Bruix, J. (2021). Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. *Medicina Clinica*, *156*(9), 463.e1-463.e30. doi: 10.1016/j.medcli.2020.09.022

Reig, Maria, Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. In Journal of Hepatology (Vol. 76, Issue 3, pp. 681–693). Elsevier B.V. doi: 10.1016/j.jhep.2021.11.018

Ruf, A., Dirchwolf, M., & Freeman, R. B. (2022). From Child-Pugh to MELD score and beyond: Taking a walk down memory lane. In Annals of Hepatology (Vol. 27, Issue 1). Elsevier Espana S.L.U. doi: 10.1016/j.aohep.2021.100535

Singal, A. G., et al. (2020). Antiviral therapy for hepatitis C and hepatocellular carcinoma risk: A systematic review and meta-analysis. *Journal of the American Medical Association, 323*(4), 364–376. doi: 10.1001/jama.2019.21526

Su, C. W., Lei, H. J., Chau, G. Y., Hung, H. H., Wu, J. C., Hsia, C. Y., Lui, W. Y., Su, Y. H., Wu, C. W., & Lee, S. D. (2012). The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: A propensity score matching analysis. *Archives of Surgery*, *147*(2), 137–144. doi: 10.1001/archsurg.2011.288

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. doi: 10.3322/caac.21660

Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020). Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. In Frontiers in Oncology (Vol. 10). Frontiers Media S.A. doi: 10.3389/fonc.2020.601710

Tandon, P., & Garcia-Tsao, G. (2009). Prognostic indicators in hepatocellular carcinoma: A systematic review of 72 studies. In Liver International (Vol. 29, Issue 4, pp. 502–510). doi: 10.1111/j.1478-3231.2008.01957.x

Tangkijvanich, P., Mahachai, V., Suwangool, P., & Poovorawan, Y. (2345). Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. *World Journal of Gastroenterology*, *10*(11). Retrieved from http://www.wjgnet.com/1007-9327/10/1547.asp

Villanueva, A. (2019). Hepatocellular Carcinoma. *New England Journal of Medicine*, *380*(15), 1450–1462. doi: 10.1056/NEJMra1713263

Yu, S. J., et al. (2019). Gender disparity of hepatocellular carcinoma: The role of sex hormones. *Oncology Letters, 17*(2), 1731–1737. doi: 10.3892/ol.2018.9784

Zhu, X. D., & Sun, H. C. (2020). Emerging role of lenvatinib for hepatocellular carcinoma. *Cancer, 126*(21), 4563–4573. doi: 10.1002/cncr.33051